Altre lingue Fortress Biotech, Inc. Nasdaq

Azioni

FBIOP

US34960Q2084

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 31/05/2024			Variaz. 5gg	Var. 1 gen.
15,87 ^USD	+1,67%		+1,73%	+33,70%

15/05	Fortress Biotech, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
14/05	Fortress Biotech dichiara che il primo paziente è stato somministrato nello studio di fase 2 di Triplex	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	14/05
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	14/05
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
FORTRESS BIOTECH, INC. : Alliance Global Partners toujours positif	19/03
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc	26/01
Fortress Biotech Prices $11 Million Offering of Stock, Warrants; Shares Sink in Early Trading	29/12
FORTRESS BIOTECH, INC. : Roth MKM réitère son opinion positive sur le titre	29/11
Top Midday Gainers	17/11
Fortress Biotech Insider Bought Shares Worth $2,664,776, According to a Recent SEC Filing	16/11
Fortress Biotech Insider Bought Shares Worth $249,999, According to a Recent SEC Filing	16/11
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10/11
Top Premarket Decliners	10/11
Fortress Biotech Begins Public Offering of Units	10/11
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)	20/10/23
Reverse Split: 1 for 15	10/10/23	FA
Fortress Biotech Announces 1-for-15 Reverse Stock Split	09/10/23
FORTRESS BIOTECH, INC. : B. Riley reste à l'achat	22/08/23
Fortress Biotech CEO Rosenwald Buys 20,000 Shares for $210,900	21/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Fortress Biotech, Inc. Nasdaq

Azioni

FBIOP

US34960Q2084

Altre lingue

Filtri